CV Technologies Launches Natural Health Product to Improve Memory

EDMONTON, ALBERTA, May 7, 2004 (CCNMatthews via COMTEX) -- (CVQ - TSX VEN). CV Technologies Inc. today launched a new scientifically proven natural therapeutic for mental alertness, memory improvement and the protection of brain cells from degeneration.

Company president, CEO & Chief Scientific Officer, Dr. Jacqueline Shan says the product - called REMEMBER-fX(R), "significantly enhances memory and cognition by increasing an important chemical in the brain which helps it to perform a key function in the process of building memories."

The discovery is the result of in-house and collaborative R & D by a team of 25 scientists over a 10-year period. The U.S. Patent Office recognized the uniqueness of REMEMBER-fX by issuing it a patent, not just for its chemical make up, but also for use of it in memory neurodegenerative diseases such as Alzheimer's and Parkinson's. This is the first time that a natural health product has received this type of patent.

Dr. Shan says, "REMEMBER-fX contains active phytochemicals and works by increasing choline uptake in the brain resulting in the increase of acetylcholine (Ach), a key neurotransmitter essential for learning and memory function. It also prevents brain cells from degeneration."

It's believed that no pharmaceutical drug or natural health product has such a unique mechanism of action in improving the memory. Acetycholine is one of hundreds of neurotransmitters whose job is to help the brain work more effectively in ferrying information from cell to cell.

Dr Shan says, "The brain is a vast complex organ with billions of brain cells, kilometers of intricate wiring and a mysterious electrochemical process that makes it work and 'creates' our memory. Memory is a key part of the fabric of who we are and when it starts to fade, part of who we are as individuals starts to fade with it. So part of our research was focused on ways to help an ailing brain to store memories."

REMEMBER-fX boosts the levels of messenger chemicals thought to be critical in the formation of memories. Studies of lab rats and mice that were given the product showed that they rapidly learned, retained and recalled tasks involving the Morris Water Maze test as well as a passive avoidance test demonstrating memory retention. A laboratory study of cultural nerve cells also indicated REMEMBER-fX could promote nerve cell growth.

University of Alberta physiology professor, Dr. Christina G. Benishin, who was involved in the early stages of research discovery/discovery involving REMEMBER-fX's effect on acytecholine and memory says, "HT-1001, the propriety active ingredient in REMEMBER-fX demonstrated memory enhancing properties".

In the area of human trials, a placebo-controlled Phase I pilot trial of REMEMBER-fX lasting two weeks was conducted involving two groups of people - one between the ages of 20-22, and the other 45-65. The results showed a 300 % increase in the memory index - a series of memory tests - for both groups. That trial and two other Phase I trials involving 101 participants also demonstrated that REMEMBER-fX is safe.

Dr. Shan said there's lots of good, exciting research underway in the area of 'clinically diagnosed' memory loss associated with dementias like Alzheimer's, but so far there are really no effective drugs for preventing or curing memory loss, "that's why we feel REMEMBER-fX is going to be a helpful addition in the fight to protect our memories from degeneration."

Dr. Shan said CVT plans to carry out advanced large scale clinical trials of REMEMBER-fX in the future.

Dr. Shan announced the launch of REMEMBER-fX at an AGM of shareholders in Calgary today.

Memory loss is a universal phenomena. Studies show that normal people experience signs of forgetfulness starting from the age of 30 and the deterioration of memory cells increases going forward. The market potential for REMEMBER-fX as a memory enhancer and preventative for nerve cell degeneration is substantial in a field where each year in Canada $5.5 billion is spent annually on Alzheimer's and other dementias. Dr. Shan said CVT's primary focus is on enhancing memory and increasing mental alertness in normal people. Hopefully studies in the future will prove it may also prevent memory from generating to a clinical dementia.

Researchers say some of the major factors that affect memory and contribute to memory loss in normal people include stress, information exhaustion and work overload as well as normal aging.

Further information regarding REMEMBER-fX is available at and will soon be offered for sale in leading pharmacies, grocery and health food stores.


CV Technologies is a biotechnology company founded in 1992. The Company aims to become the leader in discovering, developing and commercializing science and technology based patented natural therapeutics for disease prevention and health maintenance. We are committed to applying the highest standards of medical research, innovation and integrity in producing preventive medicine to improving peoples health and quality of life. CVT's lead product is COLD-fX(R), a year-round medication that an FDA regulated Phase II Clinical Trial shows reduces the risk of getting a cold or flu by 89%. As an immune booster, it is widely used year-round including the summer period during which time North Americans suffer an estimated 200 million summer colds. REMEMBER-fX is another of CVT's products and like COLD-fX, is unique because it was developed and standardized according to the Company's ChemBioPrint(TM) technology, a patented process that precisely identifies the chemical profile and biological activity of natural health products. This is a combination of chemical and pharmacological fingerprinting that ensures each batch of products delivers verifiable and provable health benefits, and is both safe and consistent with previous batches.

This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "expects" and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include, but are not limited to, the need for capital, changing market conditions, completion of clinical trials, patient enrolment rates, uncertainty of pre-clinical, retrospective and early clinical trial results, the establishment of manufacturing processes and new corporate alliances, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time to time in the Company's filings with Canadian securities authorities.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.